Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Pregabalin Capsule-Controlled, 13-Week, Adaptive-design Phase 2/3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Diabetic Peripheral Neuropathic Pain

NCT04647773 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT04647773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Pregabalin Capsule-Controlled, 13-Week, Adaptive-design Phase 2/3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Diabetic Peripheral Neuropathic Pain
Lead sponsor
Haisco Pharmaceutical Group Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
December 2, 2020
Completion date
November 16, 2022
Enrollment
687 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathic pain